Q-omics provides the consensus-scored OIP5 profile across patient tissues and cancer cell-line models. OIP5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, OIP5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, OIP5 RNA expression shows 22,625 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where OIP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OIP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OIP5 survival associations across molecular data types. OIP5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OIP5 RNA expression–survival associations across cancer types. High OIP5 expression shows unfavorable associations in KIRP, ACC, KICH, LUAD, UVM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for OIP5 RNA expression.
This table summarizes OIP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OIP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OIP5 shows higher tumor expression in HNSC, KIRC, BLCA, LUAD, KIRP and COAD. The HNSC box plot shows higher OIP5 RNA expression in tumor versus normal tissue (log2 FC = +1.561, t-test p < 0.001).
This table shows molecular features associated with OIP5 in patient tissues and cancer cell lines. In patient samples, OIP5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OIP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
